<DOC>
	<DOCNO>NCT02209896</DOCNO>
	<brief_summary>The BlueWind Reprieve system neurostimulator consist Implant external component . The system intend home care use . The chronic pain treatment achieve electrical stimulation peripheral nerve fiber . The stimulation set generates paresthesia stimulate area ( e.g . foot ) , reduce pain sensation improve quality life patient .</brief_summary>
	<brief_title>BlueWind Reprieve System Treatment PNP</brief_title>
	<detailed_description />
	<mesh_term>Neuralgia</mesh_term>
	<criteria>Signed write informed consent . Male female age 18 80 . Patient agree attend followup evaluation willing completely accurately fill pain questionnaire . Diagnosis chronic neuropathic pain due peripheral neuropathy . Documented pain attribute neuropathy least 6 month . Pain intensity average daily VAS score least 6 , demonstrate 3 rating per day across 7 day . Patient refractory conservative treatment include pain medication , least 6 month . Stable pain medication least 4 week prior study enrollment . Previous participation another study investigational drug device within past 90 day . Any active implant ( cardiac ) . Any metal implant area BlueWind device implantation site . Current pregnancy attempt get pregnant ( female patient ) . Any clinically significant neurologic disorder ( except PNP ) . Any clinically significant unstable medical psychiatric condition would affect patient 's ability participate study . Patients severe unstable cardiovascular , pulmonary , gastrointestinal , hematological , hepatic , renal endocrine disease . Severe peripheral vascular disease may cause intermittent claudication ischemic ulcer .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Peripheral Neuropathic Pain</keyword>
	<keyword>PNP</keyword>
</DOC>